🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

🧪

Trial Match

Clinical trials test new treatments — sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

🎯 Match trials to me

22 recruiting trials

for NK-T-Cell Lymphoma, Extranodal

Sintilimab With P-GEMOX Versus the P-GEMOX in the Teatment of Advanced-stage Extranodal Natural Killer/T Cell Lymphoma NCT06583083Phase 21 site📍 Guangzhou Sun Yat-sen University · Tests: Sintilimab with P-GEMOX Regimen, P-GEMOX Regimen Tislelizumab Plus Zeprumetostat for Relapsed or Refractory NK/T-Cell Lymphoma NCT07502768Phase 1, Phase 21 site📍 Shanghai Rong Tao · Tests: Tislelizumab, Zeprumetostat Clinical and Biological Cohort Study of EBV-Positive T/NK-Cell Lymphoproliferative Diseases NCT07727083n/a1 site📍 Shanghai Rong Tao A Phase II Study of Dexamethasone, Azacitidine, Pegaspargase and Tislelizumab Plus Radiotherapy for Patients With Stage I/II Extranodal NK/T-cell Lymphoma NCT07000617Phase 23 sites📍 Beijing📍 Beijing📍 Beijing Peking University Cancer Hospital & Institute · Tests: DAPT regimen plus radiotherapy Allogeneic Stem Cell Transplantation in Relapsed/Refractory T-, NK/T-cell Lymphomas NCT02859402Phase 22 sites📍 Busan📍 Daegu Keimyung University Dongsan Medical Center · Tests: Busulfan, Fludarabine RD13-02 Cell Injection in Patients with Relapsed or Refractory CD7-Positive Natural Killer/T Cell Malignancies NCT06732492Phase 11 site📍 Wuhan Union Hospital, Tongji Medical College, Huazhong University… · Tests: RD13-02 cell infusion Sintilimab and Linperlisib Combination Treatment in Relapsed or Refractory Extranodal Natural Killer/T Cell Lymphoma NCT06793956Phase 11 site📍 Guangzhou Sun Yat-sen University · Tests: Sintilimab and Linperlisib Combination Treatment Safety and Efficacy of Anti-EBV Autologous TCR-T Cell Injection in Relapsed/Refractory EBV-Positive Lymphoma NCT07162012EARLY Phase 11 site📍 Shanghai Shanghai General Hospital, Shanghai Jiao Tong University Sc… · Tests: EBV TCR-T A Registry for People With T-cell Lymphoma NCT05978141n/a26 sites📍 Duarte📍 San Diego📍 San Francisco Memorial Sloan Kettering Cancer Center · Tests: Optional Blood Sample and Nail Sample Sintilimab, Pegaspargase Plus GemOx for Untreated Extranodal NK/T-Cell Lymphoma NCT06824883Phase 21 site📍 Beijing Peking Union Medical College Hospital · Tests: Immunochemotherapy Phase II Study of Golidocitinib and Benmelstobart in Patients with R/R ENKTL (JACKPOT50) NCT06733051Phase 22 sites📍 Beijing📍 Guangzhou Sun Yat-sen University · Tests: Golidocitinib, Benmelstobart Concurrent Tislelizumab and Radiotherapy in Newly Diagnosed Extranodal NK/T-cell Lymphoma, Nasal Type NCT05477264Phase 21 site📍 Seoul Won Seog Kim · Tests: Tislelizumab PET and EBV DNA-directed Therapy for Localized Nasal Extranodal NK/T Cell Lymphoma NCT06069830NA1 site📍 Shanghai Ruijin Hospital · Tests: 4 cycles of ESA regimen with sandwiched radiotherapy, 2 cycles of ESA regimen sequential radiotherapy and 2 cycles of P… BRIDGE-NK: Immunotherapy Versus Chemotherapy Induction Followed by Autologous HSCT in Advanced NKTCL NCT07678229Phase 31 site📍 Shanghai Rong Tao · Tests: GELAD regimen, MEDA regimen, LEAP regimen, High-dose methotrexate, Autologous Hematopoietic Stem Cell Transplantation PET/MR in the Staging and Efficacy Evaluation of Newly Diagnosed NK/T-cell Lymphoma NCT05662540NA1 site📍 Shanghai Ruijin Hospital · Tests: Positron Emission Tomography/Magnetic Resonance (PET/MR) Clinical Study of XPO1 Inhibitor Selinexor Combined With COPL in Newly Diagnosed Advanced NK/T-cell Lymphoma NCT05833893Phase 21 site📍 Beijing Chinese PLA General Hospital · Tests: XPO1 inhibitor A Multicenter, Phase 3, Randomized Trial of Sequencial Chemoradiotherapy with or Without Toripalimab (PD-1 Antibody) in Newly Diagnosed Early-Stage Extranodal Natural Killer/T Cell Lymphoma, Nasal Type (ENKTL) NCT04365036Phase 31 site📍 Guangzhou Sun Yat-sen University · Tests: Toripalimab, Pegaspargase, Gemcitabine, Oxaliplatin, Definitive intensity-modulated radiotherapy (IMRT) Registry of Older Patients With Cancer NCT01137825n/a7 sites📍 Boone📍 Chapel Hill📍 Greenville UNC Lineberger Comprehensive Cancer Center Phase 1 Study of JV-394 Autologous Anti-CD94 CAR T for r/r CD94+ T/NK Cell Neoplasms NCT07382817Phase 11 site📍 Houston M.D. Anderson Cancer Center · Tests: JV-394 Tissue, Blood, and Body Fluid Sample Collection From Patients With Hematologic Cancer NCT01137643n/a1 site📍 Chapel Hill UNC Lineberger Comprehensive Cancer Center · Tests: biologic sample preservation procedure, cytology specimen collection procedure A Study of DR-01 in Subjects With Large Granular Lymphocytic Leukemia or Cytotoxic Lymphomas NCT05475925Phase 1, Phase 237 sites📍 Birmingham📍 Duarte📍 Irvine Dren Bio · Tests: DR-01 Combination of Mitoxantrone Liposome and Etoposide, Dexamethasone, Pegaspargase and Golidocitinib (MEPL-G) in the Treatment of NK/T-cell Lymphoma Associated Hemophagocytic Lymphohistiocytosis (NKTCL-HLH) NCT07525466Phase 1, Phase 21 site📍 Beijing Beijing Tongren Hospital · Tests: Mitoxantrone liposome, Etoposide, Pegaspargase (PEG) Asparaginase, methylprednisolone, golidocitinib
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy